FDA Brief

Warning letters Drugs

FDA warning letter to

Indelicare DBA INKEEZE

High riskIssued Mar 25, 2024Posted Mar 26, 2024Center for Drug Evaluation and Research | CDER

FDA warns Indelicare that its INKEEZE lidocaine numbing gel, spray and foam soap are unapproved new drugs sold outside OTC limits.

What happened

FDA reviewed the company's website in November 2023 and found three INKEEZE products sold as numbing products for use before, during and after tattooing and other cosmetic procedures. FDA said the gel and spray contain 5% lidocaine, above the 0.5% to 4% range allowed for over-the-counter external pain relievers, and that tattooing claims are not covered by the OTC rules for these products. FDA noted that as of March 22, 2024 the products were no longer on the company's website but could still be bought from third-party online sellers.

What FDA found

  1. The three products are unapproved new drugs because they do not meet the conditions for legal over-the-counter marketing.

    Section 505(a) of the FD&C Act, 21 U.S.C. 355(a)
  2. The gel and spray contain 5% lidocaine, above the 0.5% to 4% range the OTC external analgesic order allows.

    Section 505G, 21 U.S.C. 355h; OTC Monograph M017
  3. The labels and website claim the products relieve pain from tattooing, an use not allowed for these OTC products.

    Section 505G, 21 U.S.C. 355h; OTC Monograph M017
  4. The gel and spray are also labeled for hemorrhoid use, but at 5% lidocaine they cannot meet the rules for both external pain relievers and hemorrhoid products.

    OTC Monograph M015; Section 505G, 21 U.S.C. 355h
  5. The foam soap claims to reduce bacteria on skin but does not meet the OTC requirements for antiseptic products.

    Section 505G(a)(3) of the FD&C Act
  6. The products are misbranded (mislabeled in FDA's terms) because they are nonprescription drugs that do not follow section 505G and have no approved application.

    Section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)

What FDA wants

FDA asks the company to write within fifteen working days describing the specific steps taken to fix the violations, how it will prevent them from happening again, and copies of related records. If corrections cannot be finished in that time, the company must explain the delay and give a completion date.

Who should pay attention

  • tattoo studios and artists who apply numbing products before sessions
  • online retailers and distributors still selling INKEEZE numbing products
  • other makers of lidocaine numbing products marketed for cosmetic procedures

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk